Tests magnetic brain stimulation for long-lasting symptoms after COVID-19
Tests variable pulse magnetic brain stimulation in adults with post COVID-19 condition.
Plain-language title generated from the registry record
Registry title: Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation
Key facts
- Where
- Rochester, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06865222, who can take part
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06865222
- Record updated
- 19 August 2026
- Original description
The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).Read full original descriptionShow less
Variable Pulse Transcranial Magnetic Stimulation for Treatment of Post COVID Syndrome
The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).
Inclusion: Patients who have had a recent episode of COVID-19 and who present to the Post COVID-19 Clinic at Mayo Clinic Rochester with at least one of the PCC symptoms of interest - anosmia, tinnitus, fatigue. Symptoms consistent with PCC lasting at least 1 month after the positive test date. Subjects must have ongoing symptoms for > 4 weeks following the start of an acute covid infection. This is consistent with the CDC definition for post covid conditions. Start date is determined by date of first positive COVID test. There is no limitation of maximum time from acute infection start; At least one of the PCC symptoms of interest:; Anosmia: Olfactory Threshold Test scores corresponding to Anosmia or Hyposmia; Tinnitus: >0 score on Tinnitus Handicap Inventory (not present prior to SARS-COVID 2 infection); Fatigue: Total Modified Fatigue Impact Scale (MFIS) Score of 40 or above.
Exclusion: Implanted electronic devices, including pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators (VNS); Active alcohol abuse: >14 drinks a week or formal diagnosis, illicit drug use or drug abuse; Intracranial implant within 30 cm of magnet (e.g., aneurysm clips, endovascular coil, cerebral shunts, brain stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed; Previous stroke with residual deficits; Any seizure history within the past 10 years; Based on PI's or local physician's assessment that subject unable to tolerate the trial procedure due to medical condition; Any condition which in the judgment of the investigator would prevent the subject from completion of the study; Clinical abnormality or clinically unstable medical condition, as indicated by medical history, physical examination, or clinical laboratory testing, that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results; Enrolled or plans to enroll in an interventional trial during this study; Subjects unable to comprehend or follow verbal commands; Subjects unable to comprehend and sign the informed consent; Pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required for females of childbearing potential.